Sol-Gel Optimistic After Strong Q2 Financials

Sol-Gel Technologies (SLGL) has released an update.

Sol-Gel Technologies reports a promising second quarter for 2024 with a net income of $1.9 million, an increase from the previous year’s net loss, and expects its financial resources to sustain the company through early 2026. The dermatology-focused firm is progressing with pivotal clinical trials for SGT-610 and SGT-210, targeting significant markets in rare skin diseases, and has also expanded its commercial reach in Europe and South Africa for its key products, TWYNEO and EPSOLAY. Additionally, the company is undergoing executive leadership changes, with Mr. Mori Arkin set to become the interim CEO in 2025.

For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.